Why the study?
Is bedaquiline associated with adverse cardiac safety events such as QT extension in patients with MDR or XDR tuberculosis?
Is bedaquiline associated with adverse cardiac safety events such as QT extension in patients with MDR or XDR tuberculosis?
Answers are grounded in this paper and cite their sources.
Bedaquiline appears to have an acceptable cardiac safety profile in the treatment of drug-resistant tuberculosis, with QT prolongation leading to discontinuation in only a minority of patients.
The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18]. Bedaquiline is well tolerated: evidence indicates a minority of patients discontinue use due to QT extension
No takes yet. Share an insight, caveat, or question.
Pontali et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: